Key result
Renal denervation significantly improved lipid profiles in hypertensive patients at 6 months, reducing total cholesterol by 10.3 mg/dL, LDL by 7.0 mg/dL, and triglycerides by 30.7 mg/dL.
Why the study?
Preclinical studies suggest renal denervation may improve lipid profiles by reducing sympathetic activity, but its effect in hypertensive patients with or without coronary artery disease remained to be evaluated.
Does renal denervation improve lipid profiles in hypertensive patients with or without coronary artery disease?
Observational (n=122)
No
Does renal denervation improve lipid profiles in hypertensive patients with or without coronary artery disease?
Mean Difference: -10.3
p-value: p=<0.001
Renal denervation significantly improved lipid profiles in hypertensive patients, with more pronounced benefits observed in those with concomitant coronary artery disease, independent of blood pressure reduction.
RDN-linked lipid improvements in hypertension are hypothesis-generating; randomized trials needed before clinical consideration.
BACKGROUND AND AIMS: Sympathetic overactivation plays a critical role in the pathophysiology of various conditions, such as arterial hypertension, chronic kidney disease, coronary artery disease (CAD), diabetes, metabolic syndrome, and dyslipidemia. Initially developed for hypertension management, renal denervation (RDN) has also been associated with metabolic improvements. Preclinical studies in rodent models suggest that RDN may improve lipid profiles by reducing sympathetic activity. This study analyses the effect of RDN on lipid profiles in hypertensive patients with or without CAD. METHODS: This analysis includes 122 hypertensive patients with (n = 30) or without CAD (n = 92). All patients underwent radiofrequency, ultrasound, or alcohol-injection-based RDN. Fasting lipid profile, including total cholesterol, triglyceride, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and non-HDL levels was measured at baseline and 6 months after RDN in parallel to office and 24-h ambulatory blood pressure (BP). RESULTS: Six months after RDN, the total cohort showed significant lipid profile improvements. The total cholesterol levels decreased by 10.3 ± 26.3 mg/dL (p < 0.001), LDL by 7.0 ± 20.4 mg/dL (p < 0.001), and triglycerides by 30.7 ± 69.4 mg/dL (p < 0.001), while non-HDL cholesterol levels declined by 7.6 ± 26.3 mg/dL (p = 0.002). These changes were independent of BP reduction. In patients with CAD, total cholesterol levels declined by 21.7 ± 29.1 mg/dL (p < 0.001), triglycerides by 40.7 ± 80.0 mg/dL (p = 0.009), LDL by 15.2 ± 22.0 mg/dL (p < 0.001), HDL by 2.8 ± 4.7 mg/dL (p = 0.003), and non-HDL by 15.0 ± 34 .8 mg/dL (p = 0.021). Reductions in total cholesterol and LDL were greater in CAD than in non-CAD (p = 0.011 and p = 0.006). CONCLUSION: We observed a significant improvement in lipid profiles in hypertensive patients with CAD after RDN. This improvement may represent an additive benefit of RDN in hypertensive patients with CAD.
No takes yet. Share an insight, caveat, or question.
Bytyqi et al. (2025) conducted an observational in Uncontrolled hypertension with or without coronary artery disease (n=122). Renal denervation vs. Baseline (pre-procedure) was evaluated on Change in total cholesterol at 6 months (MD -10.3 mg/dL, p=<0.001). Renal denervation significantly improved lipid profiles in hypertensive patients at 6 months, reducing total cholesterol by 10.3 mg/dL, LDL by 7.0 mg/dL, and triglycerides by 30.7 mg/dL.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: